PharmPK Discussion List Archive - 2002

PharmPK Discussion List Frequently Discussed Topics

17AA and "First Pass" metabolism
3A4 substrate
6OH-Cortisol to Cortisol Ratios
Absorption rate determination
Absorption vs Elimination
Accumulation ratio calculation
Acepromazine/Propericiazine plasma levels
Active renal transporter and drug interaction
Adverse Event reporting in titrated trials
Aminoglycoside modeling
Analysis of naltrexone in human serum and urine
Analysis of QC samples
Antibodies half-life determination
Ascorbic acid analysis
Assay Accuracy and Precision - Ligand binding assay
Assay limits and precision of ligand-binding assays
Assay/content uniformity of oral dosage form in TK study
Atenolol absorption
AUC (noncompartmental vs compartmental)
AUC 0-inf
AUC calculation methods
AUC(alpha) and AUC(beta)
AUC, fm and MRT
AUC-all vs AUC-inf
AUMC also free clearance
Azamulin
Azithromycin pharmacokinetics
B/P ratios
BA and BE guidelines comparison
BA/BE ANOVA
Bayesian PK Software Survey
BE with time-dependent kinetics
Beta-interferon
Bioanalysis validation
Bioanalytical guidelines
Bioavailability and drug classes
Bioavailability fed versus fasted - amlodipine besylate
Bioavailability issues
Bioavailability question
Bioequivalence for IV?
Bioequivalence information
Bioequivalence of high first pass drugs
Bioequivalence of inhaled products
Bioequivalence Sample Size
Bioequivalence Studies in Animals
Bioequivalence study
Bioequivalence trial with alendronate.
Bleeding times following IV dosing
Blood distribution for highly protein bound compounds
Blood flow - perfusion
Blood flow rate and plasma flow rate
BLOQ data
Body mass problem in bioequivalence study
BOL in BA/BE studies
Caco-2 cells
Calculating ka
Calculation of F from blood versus urine data
Calibration samples-serial dilution
Capacity and resource planning in bioanalytical lab
Carboplatin sampling
Cell proliferation assay
Cerebrospinal fluid sampling
Circulation half-life
Citalopram enantiometrs
Class of Rifampin under BCS?
CLint Dextromethorphan, diazepam, verapamil and naloxone
Cmax/AUC
CoA reductase inhibitory potency
Cofactor for glucuronidation
Combining Mass-Balance and PK
Comparative GI transit time
Comparison of pk parameters obtained by compartmental/NCA in a dose-range study
Continuous infusion beta-lactams
Continuous infusion of nafcillin or oxacillin
Cosolvents/surfactants in iv formulations for pre-clinical studies
Creatinine Clearance in Amputees
Creatinine excretion in children
Cycloquanil
CYP 3A4 drug interaction assay
CYP2C19 substrates
Database of pharmacokinetic parameters
Daunorubicin Interaction potential
Deconvolution method
Destructive Sampling - Cmax, Tmax and AUC
Determination of half-life
Determination of tibolone in body fluid
Difference between microsomes and cDNA-expressed P450
Difference in the apparent clearance after SD versus MD
Different salts effect
Disposition of the lipid carrier and its content
Dissolution of hydrophobic Substances
Dissolution test
Distribution in diff. compartments
Distribution of PGP and CYP 3A
DMPK Departments in pharmaceutical co.
DMSO and oral absorption
DMSO Vs Propylene Glycol
Dosage adjustment for kidney impaired patient
Dose-normalized AUC's
Dosing solution verification
Doxorubicin
Drug Dissolution in Sublingual Delivery
Drug distribution into bladder tissues.
Drug interaction
Drug interaction with Ketoconazole
Drug ionization
Drug permeability
Drug stability in biological matrices
Drugs metabolized in the intestine
EC Bioequivalence
Effect of Hemolysis
Effects of handling on kinetics
Effects of milk on pharmacokinetics (Cmax, tmax) of drug
Elimination half-life and enterohepatic recirculation
Enoxaparin in hemofiltrate
Enterohepatic recirculation and determination of half-life
Enzyme drug interaction assay
Equations for steady state PK
Equivalent doses in animals
Error message in Trial Simulator
Erythromycin
Establishing the in-vivo efficacy of drug
Examples of low clearance drugs
Exclusion of subjects
Experimental permeation model
Extended Interval Dosing
Extent of Absorption
Extraction method
Extrapolated AUMC
Extrapolation of carcinogenicity
FDA Guidance(s) typos
Fellowships
First time in man
Fitting Cmax et al.
Flip-flop kinetics
Fluconazole
Food effect
Formula for steady-state 2 compartment model
Formulation Aids
Ganciclovir pk
Ganciclovyr
Gastric emptying time and diabetes
Genotyping in bioequivalence studies
Gentamicin PK
Gentamicin Population PK
Geriatric Normal height weight
GI transit time in rats
Glossary pharmacokinetics
Hepatic Impairment
Hepatocyte cultures
Hepatocyte incubation
Homocysteine analysis in blood
How to calculate intrasubject variability - Population PK
How to deal with the BLOQ values in PK and TK studies
HPLC analytical method of amlodipine
HPLC of Amoxicillin and Clavulanate
Human bioavailability values
Hump(s) at the end tail of the iv-bolus concentration-time curve
IC50 of insoluble compounds
Idarubicinol
in vitro clearance of Dextromethorphan, diazepam, verapamil and naloxone
in vivo drug distribution studies
Information regarding salivary excretion studies
Instability of benzofuraxone ring structure in blood
Insulin HPLC
Integrator option
Internal standard
Internal standard for Dissolution Study
Interspecies differences in subcutaneous PK
Intestinal permeability and Ka
Intracardiac blood removal
Inulin measurement
Invitro Invivo correlation
IOV in WinNonMix
IP dose
IS in blank, control samples
IV data for baclofen
Ketamine reference standards
Kinetica 4 and multiple dose help
Km and Vmax calculations
Lab that does allopurinol?
Lag-time
Large concentration ranges in PK analysis
LC-MS assay for amodiaquine
Levofloxacin tissue levels
Lipophillic excipient
Lisinopril PK
Liver blood flow
Loo-Riegelman and multiple doses
Lung targeting
Maximal infusion rate in the animal
Maximum IV dose
Mean Dissolution Time
Measurement of Linezolid
MEC of Ibuprofen
MEC of Naproxen, Ranitidine, Verapamil
Mechanism of Elimination from Blood for Recombinant Proteins
Menthyl chloroformate
Metabolic Stability
Metabolism in human liver microsomes mediated by CYP2D6
Metabolism of a thiazolidinedione drug
Metabolism with rat liver microsomes
Methyltestosterone
Michaelis-Menten constants
Microcal Origin routines
Midazolam analysis
Modeling Presentations
Modeling question
Modelling with extracorporeal circuits
Models for metal toxicity
Mono-Exponential Decay and One Compartment Model
Mouse intestinal microsomes
MRT
MRT Calculation
MRT po vs. iv
MRT vs half-life
Multiple Dosing : Accumulation ratio calculation
Multiple dosing code in WinNonlin
Multiple Dosing Half Life
MW cutoffs for preferred route of excretion
NaF and protein binding
Naive PK-PD Question
Naive pool vs STS vs NONMEM vs USCPACK
Nephrectomy in rats
Nimesulide parentral preparation
Non heparin anticoagulant
Non-compartmental Analysis
Non-Equilibrium PK Analysis
Non-linear kinetics
Non-linear PK?
Nonlinear pharmacokinetics
NONMEM computing times
Noradrenalin removal by haemofiltration
Octreotide and dogs
Omeprazole absorption
On-line course material in biopharmaceutics
Oral Cmax is higher than IV Cp0
Oral controlled release formulation
Oxidative metabolism with rat liver microsomes
P-gp involvement and second hump.
P-Pharm error message
P450 interaction and patient accrual
Pediatric blood volume
Pep T1 substrates + inter-patient variability
Peptides Kinetics
Permeation promoters
pH of IV vehicle - rat
Pharmacogenetics
Pharmacokinetic of drugs in eye
Pharmacokinetic parameters and profile of norgesterl
Pharmacokinetic parameters of some herbal compounds
Pharmacokinetic parameters oral drug Administration
Pharmacokinetics and diabetes
Pharmacokinetics of Ambroxol
Pharmacokinetics software for classroom use
Pharmacokinetics Tutorial
Phenytoin Clinical PK software
Phosphorylation with isolated hepatocytes
Physiological Modelling
Physiologically Based Pharmacokinetic (PBPK) Modeling
PK (clearance) and body size normalization
PK Data interpretation
PK of NSAIDS
PK parameters concerning inulin in rat
PK Terms - Swedish
PK-PD Modeling of Preclinical Data
PK-PD modelling using subjective PD end points
PK/AUC analysis
PK/PD one effect measurement
pKa of Rifapentine
Plasma and brain levels of fluoxetine
Plasma protein binding
Plasma stability standard
Plethysmography site recommendations
Polymeric forms and bioequivalence
Pooling plasma samples
Poor oral bioavailability
POPPK modelling of steady state concentaions after oral dose using Winnonmix
Population PK
Population pk data
Power of bioequivalence studies
Prediction of clearance in human
Prediction of intrinsic clearance from enzyme kinetic parameters
Prednisone blood concentration
Presence of P450's in erythrocytes
Propofol stability in blood
Pulmonary Delivery
Questions regarding AUC
R115777 assay
R2 and Standard Error
Rat parvo virus and PK
Rat Wistar with bacteria Bordetella Bronchiseptica
RBC lysates Calibration Curve
Real World multicompartment modeling
Receptor mediated clearance of peptides
Reference compound R,S Desmethyltrimipramine
References for Non-linear models
Relationship between Vz and Vss
Relationship of Vc, V2 and Q in 2-Compartment Intravascular Model
Relative BA and statistical analysis
Renal clearance
Replicate Designs
Retension of Investigational products
Risk analysis slides available
Risperidone assay
Round Up Method for Prediction of Creatinine Clearance
S-adenosylmethionine
S-mephenytoin pKa
Sample size for Intra-Patient variability
Sampling and injection sites on swine
Sampling number for population pharmacokinetics
Sampling points based on beta half-life
Saturable tissue binding mechanisms
Scaling factors
Scaling factors for in vitro CLint to in vivo hepatic intrinsic c learance
Sepsis/Septic Shock and Pharmacokinetics
Sequence Effect and Conclusion of Bioequivalence
Sequence effect at BA/BE studies
Sequential design
Sex-dependent P450 expression
Shaking Speed
Sheep plasma alpha1-acid glycoprotein concentrations
SHR-SP, its pathophysiological features
Significant digits / rounding
Simple question about Cmin,ss
Simple?
Simulated intestinal fluids
SimuSolv
Simvastatin bioanlytical services
Simvastin HPLC assay
Single dose / Multiple dose steady state BA study
Solubility and bioavailability
Solution stability
SOP about reintegration
SOP for PK reassays
Spironolactone metabolite
Stability of Fluconazole and Diltiazem
Stability/Bioavailability of Glyceryl Conjugates
Statin dose recommendations
Statistical terms
Statistical weight for calibration data
Steady state peak-trough values
Steady-state
Substrates of pgp but not CYP3A4
Sustained release candidate
t1/2 greater than MRT?
Tacrolimus AUC
Taurine conjugation
Terminology question
Testosterone MS
Therapeutic Range
Time of day kinetics?
Time of peak - two compartment
Time-dependent volume changes
Tissue Pharmacokinetics
TK parameters and blood sampling
Toxicokinetic report
Toxicology Text?
Tramadol metabolism
Transient Reduced Clearance
Tris vs Phosphate for microsomal incubations
Updata from AAPS regarding BQL
Updated ODA consensus document.
Urinary NAG and (alpha, psi)-GST Levels in Normals
Urine volume in Pregnancy
Use of sodium vapor lamps to avoid sample degradation
Using SAAM software for 0-order absorption
Using WinNonlin to analyse the replicative design for individual BE and/or Pop BE
Validation for NONMEM
Vancomycin Dosing software - PDA
Vancomycin trough levels
Vecuronium assessment by HPLC
Vecuronium assessment by hplc.
Vitamin K1 epoxide and 7-hydroxywarfarin
Volume of Blood in Brain
Volume of Distribution
Vz greater than Vss
Vz versus Vss
Walt Disney School of Pharmacokinetics
Watson Innaphase
Weighting Data and Bayesian Analysis
What do we mean by absorption?
When to do transformation of data?
WinNonlin Model
WinNonlin modeling - Baseline sample
WinNonlin user defined program question
WinNonMix vs NONMEM vs USCPACK
Xylocaine jelly penetration

Visit the PharmPK Website for more information